Drug-eluting stents. Do they make the difference?;Gli stent ricoperti di farmaci fanno davvero la differenza?

Minerva Cardioangiologica

Volumn 50, Issue 5, 2002, Pages 431-442

  Presbitero, P ^a   Asioli, M ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Coronary restenosis, prevention and control; Graft occlusion, vascular, therapy; Paclitaxel; Sirolimus

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CORTISONE; CYTOKINE; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; FK 506 BINDING PROTEIN; GROWTH FACTOR; PACLITAXEL; RAPAMYCIN; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHERECTOMY; ATHEROSCLEROTIC PLAQUE; BALLOON DILATATION; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY STENT; CYTOKINE PRODUCTION; DRUG ELUTING STENT; ELUTION; GROWTH REGULATION; HUMAN; INTIMA; MAJOR CLINICAL STUDY; RESTENOSIS; STENT; THROMBOCYTE AGGREGATION; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; ESTRADIOL; GRAFT OCCLUSION, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; MULTICENTER STUDIES; PACLITAXEL; PHARMACEUTICAL PREPARATIONS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; STENTS; TACROLIMUS; TIME FACTORS;

EID: 0036808152     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Fox R. American Heart Association 2001 scientific sessions: late-breaking science-drug-eluting stents. Circulation 2001;104:E9052.
2. Sousa JE, Costa MA, Sousa AG. What is "the matter" with restenosis in 2002? Circulation 2002;105:2932-3.
3. Morino Y, Bonneau HN. Fritzgerald PJ. Vascular brachytherapy: what have we learned from intravascular ultrasound? J Invasive Cardiol 2001;13:409-16.
4. Bult H. Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 2000;21:274-9.
5. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001;59:227-48.
6. Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv 2002A;55:409-17.
7. Teirstein PS. Living the dream of no restenosis. Circulation 2001;104:1996-8.
8. Lowe HC. Khachigian LM. Coating stents with antirestenotic drugs: the blunderbuss or the magic bullet? Circulation 2002;105:E29.
9. Beyar R, Roguin A. The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured? Eur Heart J 2001;22:2125-30.
10. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
11. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87:305-7.
12. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001;22: 2054-7.
13. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002;359:619-22.
14. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med 2002;346:1770-1.
15. Abizaid A, Dangas G, Costa M, Abizaid A, Sousa A, Serruys PW et al Sirolimus-coated stent prevents neointimal proliferation. Curr Interv Cardiol Rep 2001;3:1-4.
16. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
17. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
18. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346: 1773-80.
19. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind Ravel (Randomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
20. Serruys PW. ARTS I - the rapamycin eluting stent; ARTS II - the rosy prophecy. Eur Heart J 2002;23:757-9.
21. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 2001;86:262-4.
22. Kalinowski M Alfke H, Kleb B, Durfeld F, Joachim Wagner H. Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: possible topical application in malignant bile duct obstructions. Invest Radiol 2002;37:399-404.
23. Herdeg C, Oberhoff M, Karsch KR. Antiproliferative stent coatings: Taxol and related compounds. Semin Interv Cardiol 1998;3:197-9.
24. Kipshidze N, Moses JW, Leon MB. Paclitaxel-coated stent: is there a light at the end of the tunnel? J Am Coll Cardiol 2001;38:292-3.
25. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M jr et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95.
26. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-76.
27. de la Fuente LM, Miano J, Mrad J, Penaloza E, Yeung AC, Eury R et al. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv 2001;53: 480-8.
28. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002;105:1883-6.
29. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS. Acampado E et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106:1195-8.
30. Hong MK, Kornowski R, Bramwell O, Ragheb AO, Leon MB. Paditaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001; 12:513-5.
31. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104:473-9.
32. Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002;966: 143-57.
33. Park SH, Lincoff AM. Anti-inflammatory stent coatings: dexamethasone and related compounds. Semin Interv Cardiol 1998;3:191-5.
34. Mash B, Bheekie A, Jones PW. Inhaled vs oral steroids for adults with chronic asthma (Cochrane Review). The Cochrane Library, numer 2.
35. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29:808-16.
36. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 2002;55:250-60.
37. Zohlnhofer D, Klein CA, Richter T, Brandl R, Murr A, Nuhrenherg T et al. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Circulation 2001;103:1396-402.
38. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and Ivus after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002;39:281-7.
39. Oberhoff M, Herdeg C, Baumbach A, Karsch KR. Stent-based antirestenotic coatings (sirolimus/paclitaxel). Catheter Cardiovasc Interv 2002;55:404-8.